Data / Drug companies / Yyba Corp
Yyba Corp: 82 products in the FDA NDC directory, labeler code 73581
Yyba Corp (labeler code 73581) lists 82 products in the FDA National Drug Code Directory, covering 39 finished drugs by generic name. By type: 82 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73581
- Products in commercial distribution
- 82
- Packages
- 155
- Finished drugs by generic name
- 39
- Prescription products
- 0
- Over the counter products
- 82
- Flagged as original packager
- 72 of 72 products that carry the flag
- Started marketing in the last 12 months
- 43
- Earliest marketing start
- August 19, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 50 | 61% |
| Over the counter monograph drugs | 30 | 36.6% |
| Other unapproved drugs | 1 | 1.2% |
| New drug applications (NDA) | 1 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 82 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lidocaine | 10 | 216 |
| Fexofenadine hydrochloride | 5 | 65 |
| Pyrantel pamoate | 4 | 13 |
| Adapalene | 4 | 34 |
| Loperamide hydrochloride | 4 | 82 |
| Guaifenesin | 4 | 123 |
| Olopatadine hydrochloride | 3 | 35 |
| Clotrimazole | 3 | 98 |
| Fluticasone propionate | 3 | 71 |
| Loratadine | 3 | 125 |
| Diclofenac sodium | 3 | 109 |
| Esomeprazole magnesium | 2 | 77 |
| Levonorgestrel | 2 | 31 |
| Simethicone | 2 | 86 |
| Sodium chloride | 2 | 71 |
| Mineral oil/white petrolatum | 2 | 1 |
| Lidocaine 5% | 2 | 23 |
| Fexofenadine hcl | 2 | 39 |
| Guaifenesin, dextromethorphan hbr | 2 | 26 |
| Butenafine hydrochloride | 1 | 14 |
| Docosanol | 1 | 42 |
| Omeprazole magnesium | 1 | 21 |
| Loperamide hcl | 1 | 42 |
| Ivermectin | 1 | 33 |
| Phenazopyridine hydrochloride | 1 | 53 |
| Cetirizine hydrochloride | 1 | 119 |
| Azelastine hydrochloride | 1 | 17 |
| Lidocaine phenylephrine | 1 | 1 |
| Diphenhydramine hcl | 1 | 99 |
| Famotidine 10mg | 1 | 1 |
| Loperamide hydrochloride 2mg, simethicone 125mg | 1 | 2 |
| Levocetirizine dihydrochloride | 1 | 52 |
| Polyethylene glycol 3350 | 1 | 67 |
| Lidocaine hydrochloride | 1 | 134 |
| Phenylphrine hcl | 1 | 1 |
| Fexofenadine | 1 | 1 |
| Famotidine 20mg | 1 | 3 |
| Doxylamine succinate | 1 | 39 |
| Lidocaine and menthol | 1 | 17 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 31 | 37.8% |
| Gel | 9 | 11% |
| Cream | 9 | 11% |
| Solution | 4 | 4.9% |
| Patch | 4 | 4.9% |
| Spray, metered | 4 | 4.9% |
| Ointment | 4 | 4.9% |
| Capsule | 3 | 3.7% |
| Capsule, liquid filled | 3 | 3.7% |
| Spray | 3 | 3.7% |
| Capsule, delayed release | 2 | 2.4% |
| Liquid | 2 | 2.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pain Relief Gel-Patch | 73581-915 | Patch | Over the counter monograph drugs | November 2, 2026 |
| Diclofenac Sodium | 73581-922 | Gel | Generic drugs (ANDA) | October 13, 2026 |
| Lidocaine | 73581-900 | Spray | Over the counter monograph drugs | September 16, 2026 |
| Olopatadine hydrochloride | 73581-713 | Solution | Generic drugs (ANDA) | September 10, 2026 |
| Lidocaine Phenylephrine | 73581-910 | Spray | Over the counter monograph drugs | September 2, 2026 |
| Fluticasone | 73581-535 | Spray, metered | Generic drugs (ANDA) | September 1, 2026 |
| Fluticasone Propionate ALLERGY RELIEF | 73581-530 | Spray, metered | Generic drugs (ANDA) | September 1, 2026 |
| Fluticasone propionate | 73581-510 | Spray, metered | Generic drugs (ANDA) | September 1, 2026 |
| Clotrimazole | 73581-448 | Solution | Over the counter monograph drugs | September 1, 2026 |
| Diclofenac | 73581-410 | Gel | Generic drugs (ANDA) | September 1, 2026 |
| Loratadine | 73581-229 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Loperamide hydrochloride | 73581-177 | Capsule, liquid filled | Generic drugs (ANDA) | September 1, 2026 |
| Levonorgestrel | 73581-017 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Omeprazole | 73581-015 | Capsule, delayed release | Generic drugs (ANDA) | September 1, 2026 |
| Welmate Numbing Relief | 73581-920 | Spray | Over the counter monograph drugs | August 31, 2026 |
| Olopatadine Hydrochloride | 73581-712 | Solution | Generic drugs (ANDA) | August 31, 2026 |
| Sodium Chloride | 73581-707 | Ointment | Over the counter monograph drugs | August 20, 2026 |
| Mineral Oil/White Petrolatum | 73581-711 | Ointment | Over the counter monograph drugs | August 19, 2026 |
| Mineral Oil/White Petrolatum | 73581-710 | Ointment | Over the counter monograph drugs | August 17, 2026 |
| Lidocaine Hydrochloride | 73581-120 | Cream | Over the counter monograph drugs | August 3, 2026 |
| Ivermectin | 73581-021 | Lotion | Generic drugs (ANDA) | August 3, 2026 |
| Fexofenadine | 73581-012 | Tablet | Generic drugs (ANDA) | July 27, 2026 |
| Azelastine hydrochloride | 73581-500 | Spray, metered | Generic drugs (ANDA) | July 14, 2026 |
| Loperamide Hydrochloride | 73581-175 | Tablet | Generic drugs (ANDA) | July 13, 2026 |
| Pyrantel pamoate | 73581-110 | Liquid | Over the counter monograph drugs | July 13, 2026 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.